12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MOR208: Completed Phase I enrollment

The partners completed enrollment of 30 patients in an open-label, dose-escalation, U.S. Phase I trial evaluating MOR208. In June 2010, Xencor granted MorphoSys...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >